In vivo molecular imaging is increasingly recognized as powerful tools to study cancer, cardiovascular disease, neurological and various other disorders and to evaluate new drugs in their preclinical studies. It allows real-time, non-invasive exploration of genes, proteins, pathogens, and tumor cells in living animals, aiding in the analysis of drug distribution, side effects and the effects of new therapy.
Among many in vivo animal imaging modalities, fluorescence imaging has been mostly used for pre-clinical research and development because of its easier to use, less expensive and higher throughput technique. Fluorescence molecular imaging use either the cells transfected with fluorescent protein gene or molecular probes conjugated with fluorescence dyes measured by a fluorescence imaging system. Fluorescence imaging can be used in preclinical study to visualize and monitor disease progression, drug localization and target binding in assessment of test drug response.
Origin currently provides the following services for fluorescence molecular imaging in partnership with AntiCancer Inc.
- In vivo efficacy study in various fluorescent cancer models
- Conjugation of targeting ligands with various visible and near infrared fluorescence dyes, including antibody, peptide and nucleotide for preparation of specific fluorescence molecular probes
- In vivo fluorescence imaging with various specific fluorescence molecular probes in diseases animal models
- In vivo fluorescence imaging with various fluorescence protein gene transfected cells in diseases animal models
- Origin is currently the representative of INDEC Biosystem and distributes its FluorVivo imaging system.